Transdel Pharmaceuticals Submits to the FDA the Phase 3 Clinical Study of Ketotransdel(TM) for the Treatment of Acute Pain
           

LA JOLLA, CA--(Marketwire - February 7, 2008) -  Transdel Pharmaceuticals, Inc. (OTCBB: TDLP),
a specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically targeted medications, announced
today that it submitted its Phase 3 clinical study to the Food and Drug
Administration (FDA) for the Company's lead topical drug, KetotransdelT.
Ketotransdel is a novel, topical cream-based non-steroidal
anti-inflammatory drug (NSAID) for the treatment of acute pain. The Company
plans to initiate Phase 3 clinical trials following the FDA's 30-day review
period.

           

http://www.marketwire.com/mw/release.do?id=818583&sourceType=3